Skip Navigation

1987

Belgium
GlaxoSmithKline develops experimental malaria vaccine RTS,S. In 2009, stage 3 clinical trials begin in Africa. The vaccine is 30–50 percent effective.

 

Johns Hopkins Public Health Magazine - 2001 Malaria Special Edition